These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33525721)

  • 1. Evidence of Polyphenols Efficacy against Dry Eye Disease.
    Favero G; Moretti E; Krajčíková K; Tomečková V; Rezzani R
    Antioxidants (Basel); 2021 Jan; 10(2):. PubMed ID: 33525721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new approach for better comprehension of diseases of the ocular surface].
    Baudouin C
    J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential benefits of polyphenols for corneal diseases.
    Feng J; Zhang Y
    Biomed Pharmacother; 2023 Dec; 169():115862. PubMed ID: 37979379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry eye disease in strabismus patients: Does eye deviation harm ocular surface?
    Giannaccare G; Versura P; Sebastiani S; Fariselli C; Pellegrini M; Campos E
    Med Hypotheses; 2018 Feb; 111():15-18. PubMed ID: 29406988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
    Babizhayev MA; Kasus-Jacobi A
    Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye.
    Stonecipher KG; Torkildsen GL; Ousler GW; Morris S; Villanueva L; Hollander DA
    Clin Ophthalmol; 2016; 10():887-95. PubMed ID: 27257373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
    Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic inhibitors for the treatment of dry eye syndrome.
    Rodríguez-Pomar C; Pintor J; Colligris B; Carracedo G
    Expert Opin Pharmacother; 2017 Dec; 18(17):1855-1865. PubMed ID: 29115899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Punctal occlusion for dry eye syndrome.
    Ervin AM; Law A; Pucker AD
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006775. PubMed ID: 28649802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutical approach to dry eye syndrome].
    Babić GS; Zlatanović G; Jocić JD; Cekić S; Vujanović M
    Med Pregl; 2010; 63(11-12):793-800. PubMed ID: 21553457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of the IL-33/ST2 pathway in dry eye.
    Wang S; Zhang H
    Mol Vis; 2019; 25():583-592. PubMed ID: 31673224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discomfort symptoms reduction and ocular surface parameters recovery with Artelac Rebalance treatment in mild-moderate dry eye.
    Versura P; Profazio V; Giannaccare G; Fresina M; Campos EC
    Eur J Ophthalmol; 2013; 23(4):488-95. PubMed ID: 23539457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Tear Supplementation with 0.15% Preservative-Free Zinc-Hyaluronate on Ocular Surface Sensations in Patients with Dry Eye.
    Perényi K; Dienes L; Kornafeld A; Kovács B; Kiss HJ; Szepessy Z; Nagy ZZ; Barsi Á; Acosta MC; Gallar J; Kovács I
    J Ocul Pharmacol Ther; 2017; 33(6):487-492. PubMed ID: 28375789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel TRPM8 agonist relieves dry eye discomfort.
    Yang JM; Li F; Liu Q; Rüedi M; Wei ET; Lentsman M; Lee HS; Choi W; Kim SJ; Yoon KC
    BMC Ophthalmol; 2017 Jun; 17(1):101. PubMed ID: 28651550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role and treatment of inflammation in dry eye disease.
    Yagci A; Gurdal C
    Int Ophthalmol; 2014 Dec; 34(6):1291-301. PubMed ID: 25416345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research and development for treating devastating corneal diseases].
    Kinoshita S
    Nippon Ganka Gakkai Zasshi; 2010 Mar; 114(3):161-99; discussion 200-1. PubMed ID: 20387535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NFE2L2 activator RS9 protects against corneal epithelial cell damage in dry eye models.
    Matsuda Y; Machida M; Nakagami Y; Nakajima T; Azuma M
    PLoS One; 2020; 15(4):e0229421. PubMed ID: 32320433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dry eye disease as a complex dysregulation of the functional anatomy of the ocular surface. New concepts for understanding dry eye disease].
    Knop E; Knop N; Brewitt H
    Ophthalmologe; 2003 Nov; 100(11):917-28. PubMed ID: 14669027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients.
    Rolando M; Autori S; Badino F; Barabino S
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):271-8. PubMed ID: 19366323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
    Mah FS; O'Brien T; Kim T; Torkildsen G
    Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.